Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | THRA | P10827 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL720462 | 0.81 | ELANE (0.35) | HCAR2ALDH1A1MAPTPOLBMAPK1 | |
| SCHEMBL285817 | 0.77 | THRB (0.38) | THRBALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL285117 | 0.76 | THRB (0.50) | HCAR2THRBALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL717492 | 0.75 | CYP2C19 (0.43) | ALDH1A1CYP3A4CYP2C9CYP2C19MAPT | |
| SCHEMBL5092633 | 0.75 | MTNR1A (0.43) | HCAR2THRBALDH1A1AKT1MAPK1 | |
| SCHEMBL12112886 | 0.75 | KDM4E (0.43) | THRBALDH1A1POLB | |
| SCHEMBL16709686 | 0.74 | HCAR2 (0.51) | HCAR2THRBALDH1A1 | |
| SCHEMBL28863896 | 0.74 | HCAR2 (0.67) | HCAR2THRBALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL41557 | 0.74 | HCAR2 (0.67) | HCAR2THRBALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL28662033 | 0.73 | THRB (0.38) | HCAR2THRBALDH1A1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729203-B2 | Polymer composition | CONTAMAC LIMITED (GB) | 2014-05-20 | — | — | US | disclosed |
| EP-2427509-A1 | POLYMER COMPOSITION | Contamac Limited (GB) | 2012-03-14 | — | — | EP | disclosed |
| US-20120053313-A1 | POLYMER COMPOSITION | CONTAMAC LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| WO-2010128266-A1 | POLYMER COMPOSITION | CONTAMAC LIMITED (GB) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053313-A1 | POLYMER COMPOSITION | UACA, CRYAA, CRYZ | HCAR2 2402/4885THRB 4392/4885ALDH1A1 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.